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Abstract
Purpose A desire to incorporate broader aspects of well-
being in health economic evaluations has led to the
development of the ICEpop CAPability measure for Adults
(ICECAP-A). The ICECAP-A draws upon Amartya Sen’s
capability approach and conceptualises well-being as the
capability to achieve Stability, Attachment, Autonomy,
Achievement, and Enjoyment. The aim of this study was to
assess the psychometric performance of the ICECAP-A in
a context where patient outcomes can extend beyond
health-related quality of life.
Methods Longitudinal data were collected for 478
women with symptoms of urinary frequency and urgency,
with or without incontinence. Women were recruited
across 22 hospitals in the UK and had a mean age of 55
(SD 14). The psychometric performance of the measure
was evaluated in relation to the EuroQol Five-Dimension
Questionnaire (EQ-5D-3L) and the International Consul-
tation on Incontinence Questionnaire for Overactive
Bladder (ICIQ-OAB) and involved an assessment of
acceptability, construct validity, and responsiveness using
parametric and nonparametric methods.
Results ICECAP-A showed good convergence with the
ICIQ-OAB with 20 out of 22 expected patterns of rela-
tionship confirmed. Findings suggested that the ICECAP-A
has better discriminative properties than EQ-5D-3L and as
good as those of the ICIQ-OAB, confirming expected
associations with clinical and demographic factors. The
ICECAP-A was more responsive than EQ-5D-3L and
ICIQ-OAB to deteriorations of clinical symptoms.
Improvements in symptoms were not valued as highly as
deteriorations by either ICECAP-A or EQ-5D-3L.
Conclusions The ICECAP-A is a valid and responsive
measure capturing broad emotional and practical impacts
of urinary symptoms on women’s well-being and could be
considered for use in economic evaluations in this context.
Keywords ICECAP-A  EQ-5D-3L  Psychometric
validation  Outcome valuation  Economic evaluation 
Overactive bladder
Introduction
Consideration of health-related quality of life (HrQoL) is
an integral component of healthcare decision-making in
many systems of the developed world. HrQoL, however,
may offer limited scope when interventions result in wider
personal well-being gains [1–4] or in external effects on
groups other than the patient [5, 6]. One appropriate
framework for conceptualising these broader well-being
impacts for health policy purposes is the capability
approach [7, 8]. The capability approach was developed by
Amartya Sen as a basis for assessing well-being in terms of
what people do and are (functioning) and particularly, what
people are able to do and be (capability) in their lives [9].
While a number of capability measures have been
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developed [10–14], the ICEpop1 CAPability (ICECAP)
measures are distinct as they provide a generic measure of
capability-well-being for use in the economic evaluation of
health and social care interventions.
The ICECAP measure for the general adult population
(ICECAP-A) has recently been developed [12] and con-
ceptualises well-being as the capability of an individual to
achieve the valuable functionings of Stability, Attachment,
Autonomy, Achievement, and Enjoyment, with health
potentially being a direct determinant of functioning. Pre-
vious validation work on the ICECAP-A has suggested that
the attributes of the measure can comprehensively capture
quality of life [15] and that the measure is able to identify
expected differences in capability-well-being in a general
population sample [16]. In terms of responsiveness, small
changes in capability-well-being were evident as a result of
changes in physical and psychological health after a knee
pain intervention [17].
However, no evidence for the psychometric properties of
the ICECAP-A exists in a clinical context where there are
likely to be impacts on well-being more broadly than those
captured by conventional HrQoL measures. This paper
explores the acceptability, construct validity, and respon-
siveness of the ICECAP-A in relation to the three-level
EuroQol Five-Dimension Questionnaire (EQ-5D-3L) [18]
and the International Consultation on Incontinence Ques-
tionnaire for Overactive Bladder (ICIQ-OAB) [19] in
women with irritative lower urinary tract symptoms (LUTS)
involving urinary frequency and urgency, with or without
incontinence. The impact of these symptoms on HrQoL is
well established [20, 21], but broader well-being issues may
arise as a result of shame, embarrassment, discomfort, and
lack of confidence [22]. It is, therefore, possible that such
effects may be missed by HrQoL measures, but picked up
by measures of broader capability-well-being.
Methods
Data source
The paper relied on data from the largest observational
study undertaken to estimate the accuracy and cost-effec-
tiveness of bladder ultrasound scan in the diagnosis of
detrusor overactivity [23]. Detrusor overactivity is termed
the involuntary contraction of the detrusor muscle observed
during the filling phase of urodynamic studies and is per-
ceived to be one of the main causes of LUTS. The study
was carried out in 22 hospitals across the UK, and women
were recruited if they presented increased frequency of
urination and mild to severe urgency, with or without
urinary incontinence. Exclusion criteria involved preg-
nancy or up to 6 weeks post-partum, stress-predominant
mixed incontinence, continuous medical treatment, like
antimuscarinics, for more than 6 months, and a surgical
treatment or urodynamic studies during the past 6 months
for a bladder condition. Women in the study had a
transvaginal bladder ultrasound scan (index test) followed
by urodynamic studies (reference test). Women were ini-
tially treated conservatively. All women provided written
informed consent and were followed up for a year.
Outcome measures
The outcome measures used in the analysis included the
ICECAP-A, EQ-5D-3L, and ICIQ-OAB. These measures
were administered prior to diagnostic testing at baseline
and 6-month follow-up, while the latter two were addi-
tionally administered at the 12-month follow-up. More
information about the different measures is provided
below.
ICEpop CAPability measure for adults (ICECAP-A)
The ICECAP-A is a generic and preference-based measure
of capability-well-being [12]. It comprises five conceptual
attributes (Stability, Attachment, Autonomy, Achievement,
and Enjoyment) with each having four response options
that range from full capability to no capability. Individual
responses to the five attributes can subsequently be trans-
lated into a capability index score using a UK population
value set obtained using the best–worst scaling method
[24]. The capability index scores range from 0 to 1, indi-
cating no capability and full capability, respectively.
EuroQol Five-Dimension Questionnaire (EQ-5D-3L)
The EQ-5D-3L is a generic and preference-based measure
of HrQoL [18], comprising five conceptual attributes
(Mobility, Self-care, Usual activities, Pain and discomfort,
and Anxiety and depression). Each attribute has three
response options ranging from no problems to severe
problems. Responses to the EQ-5D-3L are used to derive a
health index score based on country-specific value sets,
which represent general population preferences for the
different health states. In this study, health index scores
were calculated using the UK value set obtained based on
the time trade-off method [25]. The scores range from
-0.594 to 1, depending on whether severe problems or no
problems are reported across the five dimensions of the
instrument. On this scale, the values of 0 and 1 represent
1 ICEPOP was a UK MRC-funded Health Services Research
Collaboration programme on Investigating Choice Experiments for
Preferences of Older People; it was the research programme in which
the first ICECAP measure was developed.
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death and full health, respectively, while values lower than
0 represent health states considered to be worse than death.
International Consultation on Incontinence Questionnaire
for Overactive Bladder (ICIQ-OAB)
The ICIQ-OAB is a urinary incontinence-specific measure
of quality of life [19]. This measure asks four questions,
each having five response options. The questions relate to:
(a) the frequency of urination during the day, (b) frequency
of nocturia, (c) frequency of having to rush to the toilet for
urination, and (d) frequency of leaking before getting to the
toilet. Responses to these questions are scored from 0 to 4,
whereby a higher score reflects increased frequency
(severity) of symptoms. A total ICIQ-OAB score is derived
by adding the scores from all responses and thus can range
from 0 to 16. Each of the four questions has a second part
intended to measure, on an 11 (0–10)-point Likert scale, the
level of ‘bother’ from the different symptoms. Although
responses to these questions are not included in the scoring
of the instrument, they are helpful in determining patient’s
priority for treatment or monitoring changes over time.
Psychometric analysis
The sample size was determined by the main study [23],
which aimed to recruit at least 600 women after loss to
follow-up. The psychometric properties of the ICECAP-A
were assessed in relation to the EQ-5D-3L and ICIQ-OAB
and involved explorations of acceptability, construct
validity, and responsiveness. Analyses for this research
were based upon women who responded at both baseline
and 6-month follow-up, allowing for the same sample to be
used in all analyses. No data imputation was performed,
and all analyses were carried out in Stata version 12MP.
Acceptability
Acceptability is a term used to reflect the perceived rele-
vance of an outcome measure to the respondents in certain
clinical contexts. Generic outcome measures, such as the
ICECAP-A and EQ-5D-3L, are developed for application
in all clinical contexts, and, therefore, demonstrating high
levels of acceptability is an important quality. The
acceptability of the ICECAP-A was approximated through
the completion rates at baseline and 6-month follow-up
[26], with rates above 95 % indicating high levels of
acceptability [27].
Validity
Construct validity relates to the degree that relationships
between a measure and other factors confirm a priori
expected patterns of relationship and comprises both con-
vergent and discriminative (known group) validity [28].
Convergent validity assesses the extent of correlation
between instruments intended to measure similar or over-
lapping constructs [28]. The convergence between the
ICECAP-A, EQ-5D-3L, and ICIQ-OAB index scores was
explored using Pearson’s correlation coefficients. Spear-
man rank correlation coefficients were used for the con-
vergence across dimension scores and between index and
dimension scores. Correlations were considered strong if
the coefficient was above 0.5, moderate if the coefficient
was between 0.3 and 0.5, and weak if the coefficient was
below 0.3 [29]. Given that the EQ-5D-3L attributes are
scored from no problems (lowest level) to severe problems
(highest level), and the ICECAP-A attributes from no
capability (lowest level) to full capability (highest level),
the scoring of the EQ-5D-3L dimensions was reversed for
the purposes of this analysis in order to allow for a more
intuitive interpretation of findings.
Discriminative or known-group validity assesses the
extent to which instruments are able to distinguish
between dissimilar constructs [28], namely constructs
differing in a trait likely to be associated with women’s
quality of life. The constructs used in the analysis related
to age, body mass index (BMI), presence of detrusor
overactivity, previous urinary surgery, and presence of
prolapse or voiding dysfunction. The four questions
included in the ICIQ-OAB, which indicate how bother-
some the frequencies of the different urinary symptoms
are to women, and which are not considered as part of the
scoring process of the ICIQ-OAB, were also used to
construct known groups. To test whether the mean index
scores of the three measures differed between known
groups, a univariate analysis using one-way ANOVA and
a Kruskal–Wallis H test was undertaken. To account for
potential confounding problems associated with univariate
analyses, a multivariate regression analysis was addition-
ally carried out using age, BMI, past surgery, presence of
detrusor overactivity, advance prolapse, and voiding dys-
function as covariates.
Responsiveness
Given that a fundamental principle underpinning health-
care interventions is the improvement of health and well-
being, it is important that instruments are also valid in a
longitudinal context. In the assessment of responsiveness,
the different measures are compared for patient groups
expected to have experienced a change in health and well-
being based on an external criterion (anchor) [26]. Three
analyses were undertaken to explore the responsiveness of
the ICECAP-A using different anchors of potential clinical
change.
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In the first analysis, changes in the scores of the three
outcome measures were assessed based on changes in the
mean self-reported ‘bother’ across individual urinary
symptoms in the ICIQ-OAB [30]. In this analysis,
responsiveness was assessed for the overall sample and for
specific subgroups (those with the same, decreased and
increased level of ‘bother’). In the second analysis, changes
in the scores of the ICECAP-A and EQ-5D-3L were
assessed relative to changes in the actual ICIQ-OAB score
and thus based on changes in the frequency of urinary
symptoms. This analysis explored changes in capability
and health index scores for those of whom ICIQ-OAB
score decreased (symptoms less frequent), increased
(symptoms more frequent), and remained the same. In the
third analysis, changes in the scores of the three measures
were assessed based on whether women felt that symptoms
were ‘improved’, ‘deteriorated’, or ‘without change’ on a
retrospective transition question.
In the absence of a gold-standard measure of HrQoL and
well-being, responsiveness was evaluated using the stan-
dardised response mean (SRM) effect size statistic, calcu-
lated as the ratio of the mean change between baseline and
follow-up index scores to the standard deviation of the
change scores [26, 31]. Alternative methods for assessing
responsiveness, such as the receiver operating character-
istic (ROC) curve analysis, which require a gold-standard
anchor, were not explored, as none of the anchors of this
study can be considered an appropriate reference standard
of a valued change of clinical symptoms by the general
public, which is inherent in the valuation of preference-
based outcome measures. Paired t tests and Wilcoxon rank
sum tests were also carried out to identify significant
changes in scores. The values 0.2, 0.5, and 0.8 were used as
thresholds for small, moderate, and large SRM statistics
[32]. Floor and ceiling effects were calculated as the pro-
portion of women selecting the response options indicating
the lowest (floor effect) or highest (ceiling effect) level of
quality of life across all attributes of each questionnaire.
Hypothetical constructs
Good measurement validation practices require an a priori
statement of hypotheses on the expected relationship
between the theoretical concepts explored [33, 34].
Therefore, hypothetical constructs were developed inde-
pendently by each author in the light of available evidence
and personal judgment before seeing any of the results.
These are available in ‘Appendices 1 and 2’. The two
overarching expectations were that the ICECAP-A would
show better convergence with the condition-specific mea-
sure than the EQ-5D-3L and that the ICECAP-A would be
more sensitive in identifying differences and changes in the
level of ‘bother’ from urinary symptoms.
Results
The primary study recruited 687 women with lower urinary
tract symptoms. Responses to at least one of the outcome
measures were provided by 655 (95.3 %) women at base-
line and 478 (69.6 %) at the 6-month follow-up period. The
results presented in this section are based on women who
responded to at least one of the outcome measures at both
baseline and 6-month follow-up (n = 478). Women had a
mean age of 55 (SD 14) and a mean weight of approxi-
mately 77 kg (SD 18), with 198 (41.4 %) women being
classified as obese based on their BMI. Most women
(44.8 %) were diagnosed with detrusor overactivity, had no
evidence of prolapse (74.2 %), and no voiding difficulties
(56.4 %). A significant proportion of women (73.2 %)
reported high levels of ‘bother’ from urinary symptoms and
had no previous urinary surgery (82.4 %). More informa-
tion about the sample characteristics is provided in
Table 1.
Table 1 Sample characteristics (N = 478)
Variable Category Frequency
(%)
Age (mean 54.69; SD 13.89)
Age groups \30 27 (5.65)
30–44 90 (18.83)
45–64 236 (49.37)
C65 125 (26.15)
Weight (mean
76.83; SD 17.87)
BMI Normal 115 (24.06)
Overweight 165 (34.52)
Obese 198 (41.42)
Urodynamic diagnosis Detrusor
overactivity
208 (44.73)
Mixed incontinence 84 (18.06)
Stress incontinence 56 (12.04)
Normal bladder 76 (16.34)
Othera 41 (8.82)
Advanced prolapse No 351 (74.21)
Yes 122 (25.79)
Voiding difficulty No 265 (56.38)
Yes 205 (43.62)
Previous urinary surgery No 389 (82.42)
Yes 83 (17.58)
Impact of symptoms
(‘bother’)
Low 42 (8.99)
Moderate 83 (17.77)
High 342 (73.23)
a Includes the diagnoses of voiding dysfunction and low compliance
Qual Life Res
123
Acceptability
Missing data for the ICECAP-A attributes ranged between
1.3 % (Autonomy) and 1.9 % (Enjoyment) at baseline, and
between 3.8 % (Achievement) and 4.6 % (Attachment) at
6-month follow-up. For the EQ-5D-3L, missing data ran-
ged between 0.6 % (Mobility and Self-care) and 0.8 %
(Pain and discomfort and Anxiety and depression) at
baseline, and between 3.3 % (Self-care and Anxiety and
depression) and 4 % (Pain and discomfort) at 6-month
follow-up. For the ICIQ-OAB, 0–1.9 % of values was
missing at baseline and 0–1.3 % at 6-month follow-up. In
all instances, completion rates were greater than 95 %
indicating a high level of acceptability.
Construct validity
The convergence between the three outcome measures is
given in Table 2. A strong correlation was found between
the capability and health index scores, and all attributes of
the EQ-5D-3L were found to have a moderate to strong
correlation with the ICECAP-A index score. All correla-
tions between the ICECAP-A and EQ-5D-3L were statis-
tically significant at the 1 % level, apart from correlations
between the ICECAP-A attribute of Attachment and the
EQ-5D-3L attributes of Mobility, Usual activities, and Pain
and discomfort. For the latter two, however, correlations
were statistically significant at the 5 % level.
Correlations between the ICECAP-A index score and
ICIQ-OAB, although being slightly higher than those
between the EQ-5D-3L index score and ICIQ-OAB (apart
from the case of frequency of nocturia), were of similar
strength. From the 17 hypothesised associations between
the ICECAP-A attributes and ICIQ-OAB (Appendix 1),
only the correlations between the frequency of urination
during the day and the attributes of Stability and Autonomy
were not statistically significant. In addition to the
hypothesised correlations, other significant correlations
were found. Attachment was significantly correlated at the
5 % level with the ICIQ-OAB score and the frequency of
leaking before urination. Finally, frequency of nocturia was
found to have a significant correlation with Autonomy (5 %
level of significance), Achievement and Enjoyment (1 %
level of significance). All correlations were in the expected
direction (Appendix 1).
The results on the discriminative validity of the different
outcome measures are presented in Table 3. According to
the a priori hypotheses (Appendix 2), the ICECAP-A was
expected to be able to discriminate among the categories of
BMI, detrusor overactivity, and the different variables
related to self-reported levels of ‘bother’ from urinary
symptoms. There were significant differences in terms of
both ICECAP-A and EQ-5D-3L among the categories of
BMI. The presence of detrusor overactivity was signifi-
cantly associated with lower levels of capability-well-being
(at the 5 % level), but only in the univariate analysis.
Significantly lower levels of HrQoL (at the 1 % level) were
also evident for those with detrusor overactivity. Statisti-
cally significant differences in capability-well-being were
evident between those with high and low levels of ‘bother’
from the different urinary symptoms, apart from the
symptom of urgency. These differences were also captured
by the ICIQ-OAB, but not from the EQ-5D-3L, which only
identified significant differences in HrQoL (at the 5 %
level) for the urinary frequency symptom, and only in the
univariate analysis.
Responsiveness
The responsiveness of the three measures for all women
and by self-reported change in the level of ‘bother’ is given
in Table 4. There were no floor effects evident for the three
measures. There was some evidence of ceiling effect for
the EQ-5D-3L, with 16 % of women at baseline and 21 %
at 6-month follow-up reporting full health. Approximately
12 % of women reported full capability at the two time
periods. Across the three responsiveness analyses, the
ICECAP-A appeared to be more responsive than the EQ-
5D-3L, but with effect sizes being trivial to small. More
specifically, for women with the same and, particularly,
increased level of ‘bother’, the ICECAP-A was found to be
more responsive in comparison with the EQ-5D-3L and
ICIQ-OAB, with effect sizes being around 0.3 (Table 4).
Even when changes in the ICECAP-A score were assessed
based on changes in the frequency of symptoms (Table 5)
or based on women’s self-perceived change of symptoms
(Table 6), the ICECAP-A was the only measure capturing
statistically significant deteriorations in clinical outcomes.
Discussion
This paper explored the psychometric properties of the
ICECAP-A in relation to the EQ-5D-3L and ICIQ-OAB in
a sample of women with lower urinary tract symptoms.
This was the first study assessing the construct validity of
the ICECAP-A in a clinical group, and the first assessing its
responsiveness in a clinical area where symptoms are likely
to affect an individual’s quality of life, or well-being, in a
much broader sense than conceptualised by conventional
health status measures.
The results provided supporting evidence for the
acceptability, construct validity, and responsiveness of the
ICECAP-A in this context. The ICECAP-A showed high
levels of acceptability, with completion rates being above
95 %. In terms of construct validity, a strong correlation
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was found between the ICECAP-A and EQ-5D-3L index
scores and with the EQ-5D-3L attribute of Anxiety and
depression. Out of the 36 correlations explored between the
two measures, only the correlation between the attributes of
Attachment and Mobility was not statistically significant,
while from the remaining correlations, 33 (94.3 %) were
statistically significant at the 1 % level. Similarly, out of
the 22 hypothesised correlations between the ICECAP-A
and ICIQ-OAB, 20 (90.9 %) appeared to be statistically
significant, with 15 (75 %) of them being significant at the
1 % level.
In terms of discriminative validity, the ICECAP-A was
found to have better discriminative properties than EQ-
5D-3L and as good as those of the condition-specific
questionnaire (ICIQ-OAB), as it was able to detect sig-
nificant differences in capability-well-being, not only
among the BMI categories, and according to the presence
or not of detrusor overactivity, but also between the dif-
ferent levels of ‘bother’ from urinary symptoms. In the
light of mixed evidence for the association between age
and quality of life in this clinical group (see Appendix 2),
no significant difference in capability-well-being was
Table 3 Discriminative (known group) validity of the ICECAP-A, EQ-5D-3L, and ICIQ-OAB (n = 478)
Variables Categories ICECAP-A EQ-5D ICIQ-OAB
Mean (SD) P value§ P value§§ Mean (SD) P value§ P value§§ Mean (SD) P value§ P value§§
Age \65 0.82 (0.18) 0.12 0.14 0.69 (0.28) 0.18 0.17 9.14 (2.72) 0.53 0.43
C65 0.85 (0.15) 0.65 (0.28) 9.31 (2.55)
BMI Normal 0.85 (0.15) 0.00**, 0.01* 0.75 (0.24) 0.00**, 0.00** 8.86 (2.56) 0.06 0.09
Overweight 0.85 (0.15) 0.69 (0.28) 8.99 (2.63)
Obese 0.80 (0.19) 0.64 (0.30) 9.53 (2.75)
Detrusor
overactivity
No 0.85 (0.16) 0.02*, 0.07 0.72 (0.26) 0.00**, 0.00** 8.73 (2.54) 0.00**, 0.00**
Yes 0.81 (0.18) 0.63 (0.31) 9.76 (2.73)
Surgery No 0.83 (0.17) 0.59 0.37 0.69 (0.28) 0.35 0.65 9.13 (2.64) 0.29 0.05
Yes 0.84 (0.17) 0.66 (0.28) 9.47 (2.85)
Advance prolapse No 0.83 (0.17) 0.97 0.81 0.69 (0.29) 0.16 0.18 9.32 (2.64) 0.06 0.02*
Yes 0.83 (0.18) 0.65 (0.30) 8.79 (2.70)
Voiding difficulty No 0.83 (0.16) 0.92 0.96 0.69 (0.27) 0.55 0.69 9.06 (2.69) 0.28 0.13
Yes 0.83 (0.18) 0.68 (0.30) 9.33 (2.63)
Bother—
frequency of
urination (day)
B5 0.87 (0.13) 0.00**, 0.01* 0.74 (0.20) 0.03* 0.07 6.86 (2.16) 0.00**, 0.00**
[5 0.82 (0.19) 0.67 (0.30) 9.77 (2.47)
Bother—
frequency of
urination
(night)
B5 0.87 (0.13) 0.00**, 0.02* 0.73 (0.23) 0.02* 0.10 7.44 (2.21) 0.00**, 0.00**
[5 0.81 (0.18) 0.67 (0.30) 9.85 (2.53)
Bother—
frequency of
rush
B5 0.87 (0.14) 0.06 0.14 0.73 (0.22) 0.19 0.29 7.00 (2.37) 0.00**, 0.00**
[5 0.82 (0.17) 0.68 (0.29) 9.52 (2.56)
Bother—
frequency of
leaking
B5 0.88 (0.13) 0.00**, 0.04* 0.74 (0.25) 0.10 0.31 7.20 (2.36) 0.00**, 0.00**
[5 0.82 (0.18) 0.68 (0.29) 9.54 (2.57)
Total impact of
symptoms
Low 0.86 (0.14) 0.00**, 0.01** 0.75 (0.19) 0.15 0.27 6.31 (2.17) 0.00**, 0.00**
Moderate 0.87 (0.13) 0.70 (0.24) 7.57 (2.15)
High 0.81 (0.18) 0.67 (0.30) 9.94 (2.39)
A priori hypothesised significant differences between known groups in the ICECAP-A index score are shown in italics
§ Results of univariate analysis
§§ Results of multivariate regression analysis using age, BMI, detrusor overactivity, surgery, advance prolapse, and voiding difficulty as
covariates
* Significant differences between groups at the 5 % level using one-way ANOVA
** Significant differences between groups at the 1 % level using one-way ANOVA
 Significant differences between groups at the 5 % level using a Kruskal–Wallis H test
 Significant differences between groups at the 1 % level using a Kruskal–Wallis H test
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hypothesised between age groups. Even though age is
expected to inhibit capability and health, this study found
no significant differences in terms of health status (EQ-
5D-3L) and capability-well-being (ICECAP-A) between
those above and below the age of 65. These findings are
in line with previous validation work on the ICECAP-A
in a general population sample [16] and are potentially
attributable to the fact that urinary symptoms might dis-
proportionately affect those employed or more socially
engaged, diluting the age effect. The absence of such
information did not enable these covariates to be con-
trolled for in the analysis.
Table 4 Responsiveness of the ICECAP-A, EQ-5D-3L, and ICIQ-OAB by self-reported change in symptoms’ bother
Floor effect (%) Ceiling effect (%) Baseline
score
Follow-up
score
Score
change
P value SRM
Baseline Follow-up Baseline Follow-up Mean (SD) Mean (SD) Mean (SD)
ICECAP-A
All women (n = 441) 0.00 0.63 11.72 12.34 0.83 (0.17) 0.81 (0.20) -0.02 (0.15) 0.02* -0.11
Increased bother (n = 132) 0.00 0.21 3.14 2.93 0.82 (0.16) 0.78 (0.22) -0.05 (0.15) 0.00**, -0.32a
Same bother (n = 46) 0.00 0.00 1.67 0.84 0.78 (0.22) 0.74 (0.22) -0.03 (0.17) 0.17 -0.21a
Lower bother (n = 263) 0.00 0.42 6.90 8.58 0.84 (0.17) 0.84 (0.19) 0.00 (0.15) 0.86 0.01
EQ-5D-3L
All women (n = 452) 0.00 0.00 15.90 20.71 0.68 (0.28) 0.66 (0.33) -0.02 (0.25) 0.15 -0.07
Increased bother (n = 135) 0.00 0.00 5.44 4.81 0.69 (0.28) 0.64 (0.33) -0.05 (0.24) 0.02*, -0.21a
Same bother (n = 47) 0.00 0.00 1.67 1.88 0.59 (0.38) 0.57 (0.39) -0.02 (0.22) 0.50 -0.10
Lower bother (n = 270) 0.00 0.00 8.79 14.02 0.69 (0.26) 0.69 (0.32) 0.00 (0.26) 0.97 0.00
ICIQ-OAB
All women (n = 454) 0.00 0.00 0.00 1.05 9.20 (2.67) 7.31 (3.33) -1.89 (3.01) 0.00**, -0.63b
Increased bother (n = 136) 0.00 0.00 0.00 0.00 8.68 (2.48) 8.76 (2.98) 0.07 (2.16) 0.69 0.03
Same bother (n = 46) 0.00 0.00 0.00 0.00 10.39 (3.42) 10.11(3.52) -0.28 (2.43) 0.43 -0.12
Lower bother (n = 272) 0.00 0.00 0.00 1.05 9.25 (2.56) 6.11 (2.87) -3.14 (2.82) 0.00**, -1.12c
* Significant changes at the 5 % level using a paired t test
** Significant changes at the 1 % level using a paired t test
 Significant changes at the 5 % level using a Wilcoxon rank sum test
 Significant changes at the 1 % level using a Wilcoxon rank sum test
 The values of 0.2, 0.5 and 0.8 represent the cut-off points for small (a), moderate (b), and large (c) standardised response mean (SRM) effect
sizes [32]
Table 5 Responsiveness of the
ICECAP-A and EQ-5D-3L by
change in symptoms’ frequency
(i.e. ICIQ-OAB score)
Baseline score Follow-up score Score change P value SRM
Mean (SD) Mean (SD) Mean (SD)
ICECAP-A
Improved (n = 272) 0.85 (0.17) 0.85 (0.18) 0.00 (0.15) 0.96 0.00
Same level (n = 75) 0.79 (0.18) 0.76 (0.21) -0.03 (0.13) 0.06 -0.23a
Deteriorated (n = 97) 0.80 (0.18) 0.74 (0.22) -0.06 (0.18) 0.00**, -0.32a
EQ-5D-3L
Improved (n = 280) 0.70 (0.26) 0.70 (0.30) 0.00 (0.25) 0.77 0.02
Same level (n = 75) 0.66 (0.31) 0.61 (0.36) -0.05 (0.24) 0.08 -0.21a
Deteriorated (n = 97) 0.64 (0.31) 0.59 (0.37) -0.05 (0.26) 0.04* -0.21a
* Significant changes at the 5 % level using a paired t test
** Significant changes at the 1 % level using a paired t test
 Significant changes at the 5 % level using a Wilcoxon rank sum test
 Significant changes at the 1 % level using a Wilcoxon rank sum test
 The values of 0.2, 0.5 and 0.8 represent the cut-off points for small (a), moderate (b), and large
(c) standardised response mean (SRM) effect sizes [32]
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The responsiveness analyses explored changes in the
ICECAP-A index score in response to changes in the level
of ‘bother’ and frequency as well as in response to self-
perceived change of urinary symptoms. The results indi-
cated that the ICECAP-A was more responsive to a dete-
rioration of women’s symptoms compared with the EQ-
5D-3L in all responsiveness analyses and also compared
with the ICIQ-OAB when ‘bother’ and self-perceived
change of symptoms were used as anchors. Thus, deteri-
orations in clinical outcomes appeared to be ‘valued’ more
highly than improvements by the ICECAP-A, in line with
previous evidence [17], even though this could be due to
the baseline distribution of scores.
The study benefited from a relatively large sample size
and the use of longitudinal data, which enabled a thorough
assessment of both construct validity and responsiveness.
In addition, given that the assumption of normality
underpinning parametric tests is often violated in quality of
life data, nonparametric tests were also included in the
analysis. Although evidence exists in support of parametric
tests even in violations of the normality assumption [35],
the results obtained from the two tests were sometimes
contradictory.
Nevertheless, there are a number of caveats worth
highlighting in the interpretation of the study’s findings.
First, in the absence of a gold-standard measure of well-
being, the psychometric properties of the ICECAP-A could
only be investigated against hypothetically developed
constructs and imperfect anchors of clinical change. Sec-
ond, the primary study was designed to test the accuracy
and cost-effectiveness of a diagnostic strategy, rather than
the clinical effectiveness of an intervention. Because of
limitations in the primary data, it is uncertain whether there
were other health or well-being impacts, such as an unre-
lated adverse health event, that a woman might have
experienced that could have influenced the generic health
or well-being measures of this study. Finally, the primary
study targeted only women with symptoms of urinary
urgency and frequency, with or without urinary inconti-
nence, and thus, findings are restricted to the specific
sample used. Strengths and limitations associated with the
primary study, from which the data were drawn, can be
found in the full Health Technology Assessment report
[23].
There are potentially several reasons explaining the
good psychometric performance of the ICECAP-A in this
clinical group. First, the ICECAP-A comprises conceptual
attributes that capture a broader evaluative space that
extends beyond HrQoL to the capability to function in
terms of Stability, Attachment, Autonomy, Achievement and
Enjoyment. This allows for more extensive practical and
emotional implications from urinary symptoms to be cap-
tured. Intuitively, it might be expected that, in this clinical
group, symptoms of urgency or incontinence would be
significantly correlated with the EQ-5D-3L attribute of
Anxiety and depression [20, 36, 37]. However, this was not
evident in this study. While the EQ-5D-3L attribute of
Usual activities might capture some broader practical
implications of urinary symptoms, the emotional ones
appear to be largely missed. This also possibly explains
Table 6 Responsiveness of the
ICECAP-A, EQ-5D-3L, and
ICIQ-OAB by self-perceived
change of symptoms
Baseline score Follow-up score Score change P value SRM
Mean (SD) Mean (SD) Mean (SD)
ICECAP-A
Improved (n = 136) 0.86 (0.14) 0.86 (0.16) 0.00 (0.14) 0.97 0.00
Same level (n = 104) 0.83 (0.17) 0.81 (0.19) -0.02 (0.15) 0.11 -0.16
Deteriorated (n = 48) 0.79 (0.19) 0.73 (0.24) -0.07 (0.15) 0.00**, -0.45a
EQ-5D-3L
Improved (n = 140) 0.71 (0.26) 0.71 (0.29) 0.00 (0.21) 0.79 -0.02
Same level (n = 107) 0.64 (0.30) 0.64 (0.33) 0.01 (0.27) 0.84 0.02
Deteriorated (n = 50) 0.65 (0.26) 0.55 (0.39) -0.10 (0.33) 0.04* -0.31a
ICIQ-OAB
Improved (n = 139) 8.90 (2.55) 6.04 (3.06) -2.86 (3.32) 0.00**, -0.86c
Same level (n = 113) 9.12 (2.58) 7.94 (3.04) -1.18 (2.50) 0.00**, -0.47a
Deteriorated (n = 49) 8.80 (2.70) 8.45 (3.57) -0.35 (2.63) 0.36 -0.13
* Significant changes at the 5 % level using a paired t test
** Significant changes at the 1 % level using a paired t test
 Significant changes at the 5 % level using a Wilcoxon rank sum test
 Significant changes at the 1 % level using a Wilcoxon rank sum test
 The values of 0.2, 0.5 and 0.8 represent the cut-off points for small (a), moderate (b), and large
(c) standardised response mean (SRM) effect sizes [32]
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why in this study the EQ-5D-3L was not able to distinguish
between different levels of ‘bother’ from urinary symp-
toms, a finding that confirms previous validation work
which found no association between symptom severity and
the EQ-5D-3L index score and attributes [38].
Second, the ICECAP-A has more response options than
the EQ-5D-3L, which in turn may allow for a greater
degree of sensitivity and smaller floor and ceiling effects.
In this study, 16 and 21 % of women reported full health at
baseline and 6-month follow-up, respectively, whereas
approximately 12 % of women reported full capability at
the two time-points. Of course, this issue might be ame-
liorated with the development of the new five-level EQ-5D
(EQ-5D-5L) [39]. Finally, another driver of the good per-
formance of the ICECAP-A is the lower statistical dis-
persion observed in the results, which subsequently made
the different statistics more favourable compared to the
EQ-5D-3L, even when absolute changes were of similar or
smaller magnitude. This might be an implication arising
from the wider scale of values generated from the EQ-5D-
3L, which can range from -0.594 to 1 and not necessarily
between 0 and 1 as the ICECAP-A. This, however, allows
for larger changes to be seen, especially when interventions
are aimed at those with low levels of health.
More research is required in order to establish the psy-
chometric performance of the ICECAP-A. Comparisons
with other capability measures (e.g. ASCOT [40] or
OxCap-MH [11]) or other measures of HrQoL (e.g. EQ-
5D-5L [39] or SF-6D [41, 42]), and in different settings are
required to shed further light on its measurement proper-
ties. Given that recent recommendations for the evaluation
of social care interventions, published by the National
Institute for Health and Care Excellence (NICE) in the UK,
suggest a parallel use of an ICECAP measure when capa-
bility benefits are relevant [43], further research is required
to establish the validity and responsiveness of the ICECAP-
A in different social care contexts. Finally, given the lim-
ited empirical evidence for the validity and responsiveness
of the measure in the evaluation of physical health prob-
lems, further research is required to establish the sensitivity
of the measure to capture differences and changes in
physical health status.
In conclusion, the findings of this study have provided
strong evidence for the construct validity and responsive-
ness of the ICECAP-A and support its use in the economic
evaluation of interventions for urinary symptoms in
women. Using the ICECAP-A in this context will allow for
a more holistic assessment of women’s experience of uri-
nary symptoms and treatment outcomes.
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Appendix 1
Correlations between the ICECAP-A and ICIQ-OAB that
were expected by the authors to be significant at the 5 %
level (4) or not (7) based on available evidence from the
literature and their personal opinion before the statistical
analysis.
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Evidence upon which correlations
where hypothesised
• Frequency of urination tends to impact on social
function, general and mental health and often results in
sleep problems [44, 45].
• Urgency and nocturia tend to have a significant impact
on quality of life dimensions, such as physical
functioning, pain, general health, vitality, social func-
tioning, physical and emotional role, mental health and
sleep [44–47].
• Urinary incontinence affects daily life activities, limits
behaviour, and also has a psychosocial impact [38, 48].
Appendix 2
Associations between the ICECAP-A index score and
different indicators that were expected by the authors to be
significant at the 5 % level (4) or not (7) based on avail-
able evidence from the literature and their personal opinion
before the statistical analysis.
ICIQ-OAB ICECAP-A
Capability index score Stability Attachment Autonomy Achievement Enjoyment
ICIQ-OAB score 4 4 7 4 4 4
Frequency of urination (day) 4 4 7 4 4 4
Frequency of urination (night) 4 4 7 7 7 7
Frequency of rush for urination 4 4 7 4 4 4
Frequency of leaking before urination 4 4 7 4 4 4
Correlations were expected to be negative and in the weak range
Variables Expected
association
Evidence upon which associations where hypothesised
Age (\65, C65) 7 Evidence for the relationship between age and quality of life among people
with symptoms of OAB is contradictory [21, 49, 50]
BMI (normal, overweight, obese) 4 Evidence for BMI suggests a significant association with quality of life
measured with disease-specific and general measures of HrQoL [21, 49–51]
Clinical diagnosis (overactive bladder, mixed
incontinence, stress incontinence)
7 The type of clinical diagnosis among individuals with symptoms of OAB is
not a significant determinant of quality of life [49, 52]
Detrusor overactivity (no, yes) 4 Quality of life appears to be impaired among those with an urodynamically
verified detrusor overactivity [53]
Surgery (no, yes) 7 Evidence for the relationship between quality of life and previous urinary
surgery, presence of prolapse or existence of voiding difficulties is scarce
and contradictory [20, 45, 50]
Advance prolapse (no, yes) 7
Voiding difficulty (no, yes) 7
Bother—frequency of urination (day) (B5,[5) 4 There is robust evidence, indicating that OAB symptoms severity significantly
impacts on quality of life and can be captured by both generic measures, like
the EQ-5D, and disease-specific [44, 49, 54, 55]. For the EQ-5D, however,
there has been evidence, indicating that severity is not significantly
associated with HrQoL [38]
Bother—frequency of urination (night) (B5,[5) 4
Bother—frequency of rush (B5,[5) 4
Bother—frequency of leaking (B5,[5) 4
Total bother of symptoms (low, moderate, high) 4
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